Literature DB >> 29748889

Adjuvant Radiation is Associated with Improved Survival for Select Patients with Non-metastatic Adrenocortical Carcinoma.

Daniel W Nelson1, Shu-Ching Chang2, Brad C Bandera1, Trevan D Fischer1, Robert Wollman3, Melanie Goldfarb4,5.   

Abstract

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy for which surgery is the mainstay of treatment and for which adjuvant radiation is infrequently employed; however, small, single-institution series suggest adjuvant radiation may improve outcomes.
METHODS: All patients with non-metastatic ACC treated with either surgery alone or surgery followed by adjuvant radiation were identified in the 2004-2013 National Cancer Database. Factors associated with receipt of radiation and the impact of adjuvant radiation on survival were determined by multivariable analysis.
RESULTS: Of 1184 patients, 171 (14.4%) received adjuvant radiation. Patient demographics were similar between the two groups, but those receiving radiation were more likely to have had positive margins following surgery (37.4 vs. 14.6%; p < 0.001), evidence of vascular invasion (14.0 vs. 5.1%; p = 0.05), and receive concurrent chemotherapy (57.3 vs. 28.8%; p < 0.001). After adjustment for tumor and other treatment factors, only positive margins following surgery was associated with an increased likelihood of receiving adjuvant radiation (odds ratio 3.84, 95% confidence interval [CI] 1.95-7.56). Radiation therapy did not confer a difference in median overall survival in the general cohort. However, for patients with positive margins, adjuvant radiation was associated with a 40% decreased yearly risk of death after adjustment for concurrent chemotherapy (hazard ratio 0.60, 95% CI 0.40-0.92; p = 0.02). This survival advantage was not evident for other traditional high-risk features.
CONCLUSION: Adjuvant radiation appears to decrease the risk of death in ACC patients with positive margins following surgical resection, but only a small percentage are currently receiving radiation. Multidisciplinary treatment with surgery and radiation should be considered for these patients.

Entities:  

Mesh:

Year:  2018        PMID: 29748889     DOI: 10.1245/s10434-018-6510-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Metastatic Adrenocortical Carcinoma: a Single Institutional Experience.

Authors:  Dwight H Owen; Sandipkumar Patel; Lai Wei; John E Phay; Lawrence A Shirley; Lawrence S Kirschner; Carl Schmidt; Sherif Abdel-Misih; Pamela Brock; Manisha H Shah; Bhavana Konda
Journal:  Horm Cancer       Date:  2019-08-29       Impact factor: 3.869

2.  H-score of 11β-hydroxylase and aldosterone synthase in the histopathological diagnosis of adrenocortical tumors.

Authors:  Yi Yang; Ming Xiao; Ying Song; Yi Tang; Ting Luo; Shumin Yang; Wenwen He; Qingfeng Cheng; Linqiang Ma; Yao Zhang; Yunfeng He; Youde Cao; Jun Yang; Bin Peng; Jinbo Hu; Qifu Li
Journal:  Endocrine       Date:  2019-07-22       Impact factor: 3.633

3.  Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma.

Authors:  Laila A Gharzai; Michael D Green; Kent A Griffith; Tobias Else; Charles S Mayo; Elizabeth Hesseltine; Daniel E Spratt; Edgar Ben-Josef; Aaron Sabolch; Barbara S Miller; Francis Worden; Thomas J Giordano; Gary D Hammer; Shruti Jolly
Journal:  J Clin Endocrinol Metab       Date:  2019-09-01       Impact factor: 6.134

Review 4.  Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Ther Adv Chronic Dis       Date:  2021-07-20       Impact factor: 5.091

Review 5.  Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions.

Authors:  Sara Bedrose; Marilyne Daher; Lina Altameemi; Mouhammed Amir Habra
Journal:  Cancers (Basel)       Date:  2020-02-22       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.